Alterations in gene promoter methylation and transcript expression induced by cisplatin in comparison to 5-Azacytidine in HeLa and SiHa cervical cancer cell lines

Molecular and Cellular Biochemistry

Volumn 404, Issue 1-2, 2015, Pages 181-191

  Sood, Swati ^a   Srinivasan, Radhika ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

5 Azacytidine; Cisplatin; HeLa; Methylation; SiHa; Transcript expression

Indexed keywords

AZACITIDINE; CISPLATIN; TUMOR PROTEIN;

ARTICLE; CANCER INHIBITION; CELL VIABILITY; CERVICAL CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DAPK1 GENE; DEMETHYLATION; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG EFFECT; EPIGENETICS; ESR1 GENE; FEMALE; GENE EXPRESSION; HELA CELL LINE; HTERT GENE; HUMAN; HUMAN CELL; MLH1 GENE; MYOD1 GENE; ONCOGENE; PROMOTER REGION; RASSF1A GENE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; CPG ISLAND; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INDIA; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

APOPTOSIS; AZACITIDINE; CELL PROLIFERATION; CISPLATIN; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; INDIA; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; UTERINE CERVICAL NEOPLASMS;

EID: 84941736625     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2377-3     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917
2. Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S et al (2013) Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci 14:21087–21113
3. Kulis M, Esteller M (2010) DNA methylation and cancer. Adv Genet 70:27–56
4. Bhatt AN, Mathur R, Farooque A, Verma A, Dwarakanath B (2010) Cancer biomarkers-current perspectives. Indian J Med Res 132:129–149
5. Goffin J, Eisenhauer E (2002) DNA methyltransferase inhibitors—state of the art. Ann Oncol 13:1699–1716
6. Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH et al (2005) Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 4:1505–1514
7. Macciò A, Madeddu C (2013) Cisplatin: an old drug with a newfound efficacy-from mechanisms of action to cytotoxicity. Expert Opin Pharmacother 14:1839–1857
8. Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S et al (2006) Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol 29:471
9. Fuertes MA, Alonso C, Pérez JM (2003) Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 103:645–662
10. Dong SM, Kim HS, Rha SH, Sidransky D (2001) Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 7:1982–1986
11. Zhai Y, Bommer GT, Feng Y, Wiese AB, Fearon ER, Cho KR (2010) Loss of estrogen receptor 1 enhances cervical cancer invasion. Am J Pathol 177:884–895
12. Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D (2003) The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res 9:2981–2984
13. Yu MY, Tong JH, Chan PK, Lee TL, Chan MW, Chan AW et al (2003) Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int J Cancer 105:204–209
14. Widschwendter A, Muller HM, Fiegl H, Ivarsson L, Wiedemair A, Muller-Holzner E, Goebel G, Marth C, Widschwendter M (2004) DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 10:565–571
15. Kang S, Kim JW, Kang GH, Park NH, Song YS, Kang SB et al (2005) Polymorphism in folate-and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 96:173–180
16. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H et al (2004) Promoter hypermethylation of FANCF disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 64:2994–2997
17. Wisman GB, Knol AJ, Helder MN, Krans M, de Vries EG, Hollema H et al (2001) Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer 91:658–664
18. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821–9826
19. Yu J, Zhang H, Gu J, Lin S, Li J, Lu W, Wang Y, Zhu J (2004) Methylation profiles of thirty four promoterCpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 4:65
20. Momparler RL (2003) Cancer epigenetics. Oncogene 22:6479–6483
21. Christman JK (2002) 5-Azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21:5483–5495
22. Schaefer M, Hagemann S, Hanna K, Lyko F (2009) Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res 69:8127–8132
23. Jacobs AJ, Dawoud L, Kovacs Z, Ratliff TL (1989) Inhibition of proliferation of lines derived from human cervical carcinomas by cytotoxic drugs and by recombinant interferons. Gynecol Oncol 32:31–36
24. Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D (2005) Biological and chemical inhibitors of NF-κB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 44:51–59
25. Alexander VM, Roy M, Steffens KA, Kunnimalaiyaan M, Chen H (2010) Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. Int J Clin Expl Med 3:95
26. Schneider-Stock R, Diab-Assef M, Rohrbeck A, Foltzer-Jourdainne C, Boltze C, Hartig R et al (2005) 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45-and p53-dependent mechanisms. J Pharmacol Exp Ther 312:525–536
27. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V et al (2006) Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 15:114–123
28. Koul S, McKiernan J, Narayan G, Houldsworth J, Bacik J, Dobrzynski D et al (2004) Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer 3:16
29. Yoo HJ, Byun HJ, Kim BR, Lee KH, Park SY, Rho SB (2012) DAPk1 inhibits NF-κB activation through TNF-α and INF-γ-induced apoptosis. Cell Signal 24:1471–1477
30. Liu AQ, Ge LY, Lu XL, Luo XL, Cai YL, Ye XQ, Geng FF (2014) Silencing of the hTERT gene by shRNA inhibits colon cancer SW480 cell growth in vitro and in vivo. PLoS One 10(9):e107019. doi:10.1371/journal.pone.0107019
31. Shi YA, Zhao Q, Zhang LH, Du W, Wang XY, He X, Wu S, Li YL (2014) Knockdown of hTERT by siRNA inhibits cervical cancer cell growth in vitro and in vivo. Int J Oncol 45:1216–1224
32. Tu CC, Kumar VB, Day CH, Kuo WW, Yeh SP, Chen RJ, Liao CR, Chen HY, Tsai FJ, Wu WJ, Huang CY (2013) Estrogen receptor α (ESR1) over-expression mediated apoptosis in Hep3B cells by binding with SP1 proteins. J Mol Endocrinol 51(1):203–212
33. Donninger H, Clark JA, Monaghan MK, Schmidt ML, Vos M, Clark GJ (2014) Cell cycle restriction is more important than apoptosis induction for RASSF1A protein tumor suppression. J Biol Chem 289(45):31287–31295
34. Zhong Z, Dong Z, Yang L, Chen X, Gong Z (2013) MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells. Tumour Biol 34:1959–1965
35. Fukuhara S, Chang I, Mitsui Y, Chiyomaru T, Yamamura S, Majid S et al (2014) DNA mismatch repair gene MLH1 induces apoptosis in prostate cancer cells. Oncotarget 30(5):11297–11307